This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Feuerstein's Biotech-Stock Mailbag: Elan

Add in Tysabri uncertainty. Re-occurrence of the serious brain infection known as progressive multifocal leukoencephalopathy (PML) was expected -- warnings are in the Tysabri label -- and the two patients diagnosed with PML are alive. That's where the good news ends because it seems likely that doctors will be much more cautious about prescribing Tysabri to their multiple sclerosis patients going forward.

Sure, the diehard Elan bulls may hang on somewhat, but many of them were selling Wednesday when the bapineuzumab data came up lame. The hit from Tysabri, just a day later, is like the Wall Street version of a waterboarding. Even the very strongest hands are likely to succumb.

Consider this: The value of Fidelity Investment's massive 15% stake in Elan fell more than $900 million after the bapineuzumab data were presented. Based on Elan's after-hours swoon Thursday, the value of Fidelity's Elan investment fell $1.5 billion.

Even for Fidelity, that's a lot of money. If the mutual fund giant starts selling Elan, if it hasn't already, the stock is not going to recover anytime soon.

Let's talk valuation. Natixis Bleichroeder analyst Corey Davis, a table-pounding Elan bull, pegged Tysabri's value at $13 a share. That was before the new cases of PML popped up. He gave Elan another $3 a share in value for the base business, which includes drug delivery, and $24 a share for bapineuzumab.

Davis is not giving up on bapineuzumab, in fact, he appears to be doubling down, but just about everyone else is. So, scratch the $24 a share from his model and you're left with Elan trading at $16 a share, before this latest Tysabri scare.

The European pharma analyst at UBS puts Elan's fair value, ex-bapineuzumab, at $18 a share. That's the same guess at valuation offered to me by several Elan short-sellers Wednesday at the ICAD conference, by the way. Again, this is all before Thursday night's Tysabri shocker.

2 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,054.31 +75.18 0.44%
S&P 500 1,993.14 +6.63 0.33%
NASDAQ 4,530.5380 +4.0560 0.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs